Short Interest in Coloplast A/S (OTCMKTS:CLPBY) Grows By 264.4%

Coloplast A/S (OTCMKTS:CLPBY) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 280,600 shares, an increase of 264.4% from the February 28th total of 77,000 shares. Based on an average daily volume of 482,700 shares, the days-to-cover ratio is currently 0.6 days.

Analysts Set New Price Targets

Several research analysts have recently issued reports on CLPBY shares. Sanford C. Bernstein upgraded shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th. Royal Bank of Canada upgraded shares of Coloplast A/S from a “hold” rating to a “moderate buy” rating in a research note on Monday, March 3rd. Finally, UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th.

Coloplast A/S Stock Up 0.2 %

OTCMKTS CLPBY traded up $0.02 on Friday, reaching $10.52. The stock had a trading volume of 94,249 shares, compared to its average volume of 200,453. Coloplast A/S has a 12-month low of $10.31 and a 12-month high of $14.14. The business’s 50-day moving average price is $11.00 and its 200 day moving average price is $11.92. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.02 and a quick ratio of 0.66.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings results on Tuesday, February 4th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.01). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. Equities research analysts forecast that Coloplast A/S will post 0.31 earnings per share for the current fiscal year.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.